查看文章

Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)(also termed vaccine-induced thrombotic thrombocytopenia or vaccine-induced immune thrombocytopenia or thrombosis with thrombocytopenia syndrome (TTS) by the CDC and FDA) is characterized by (i) venous or arterial thrombosis;(ii) mild to severe thrombocytopenia;(iii) positive antiplatelet factor 4 (PF4)–polyanion antibodies or anti-PF4-heparin antibodies detected by the HIT (heparininduced thrombocytopenia) ELISA assay (iv) occurring five to 24 days after ChAdOx1 nCoV-19 or Ad26. COV2. S vaccination [1]. In initial reports, patients were likely young and under 50 years, female (more than two thirds), median platelet counts at diagnosis about 20 to 30× 109 L− 1, no risk factors for thrombosis and faced unusual sites for thrombosis including cerebral sinus venous thrombosis (more than two thirds) or portal vein with high fatality rates. VITT is …